Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 135 of 151

  1. VIR-2218

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  2. VIR-2218

    Alnylam Netherlands B.V.

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  3. VIR-2218-1006

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  4. VIR-2482 (450 mg)

    Vir Biotechnology

    Influenza A

    phase 2 mab terminated

    1 trial

  5. VIR-3434

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  6. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  7. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  8. VIR-CHDV-V206

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  9. VIR-MHB1-V200

    Vir Biotechnology

    Chronic Hepatitis B Virus (HBV) Infection

    phase 2 small molecule active

    1 trial

  10. VIVITROL (Naltrexone extended-release injectable suspension)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  11. VIZAMYL 400 MBq/mL solution for injection

    Fondazione Telethon ETS

    cardiac amyloidosis

    phase 2 small molecule active

    1 trial

  12. VK-2019

    Cullinan Therapeutics

    Nasopharyngeal Carcinoma

    phase 2 small molecule terminated

    1 trial

  13. VK2809

    Viking Therapeutics

    Hyperlipidemia

    phase 2 small molecule completed

    1 trial

  14. VK2809

    Viking Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  15. VK5211

    Viking Therapeutics

    Hip Fractures

    phase 2 small molecule completed

    1 trial

  16. VLA2001

    United Therapeutics Europe Ltd

    SARS-CoV-2 Virus Infection

    phase 2 mab completed

    1 trial

  17. VLY-686

    Vanda Pharmaceuticals Netherlands B.V.

    Treatment-resistant Pruritus Associated With Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  18. VLY-686 (Tradipitant)

    Vanda Pharmaceuticals Netherlands B.V.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  19. VMP001

    United Therapeutics Europe Ltd

    Malaria

    phase 2 mab completed

    1 trial

  20. VOR33

    Vor Biopharma

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  21. VOX

    Gilead Sciences Ireland UC

    Hepatitis C Virus Infection

    phase 2 small molecule completed

    1 trial

  22. VP-102 Cantharidin topical film forming solution

    Verrica Pharmaceuticals

    Common Wart

    phase 2 other completed

    1 trial

  23. VP-102 and applicator

    Verrica Pharmaceuticals

    Condylomata Acuminata

    phase 2 other completed

    1 trial

  24. VP-102 with applicator

    Verrica Pharmaceuticals

    Molluscum Contagiosum

    phase 2 other completed

    1 trial

  25. VP-C21-011

    Lacuna Pharma Pty Ltd

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  26. VP20621

    Takeda

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  27. VPD-737

    VYNE Therapeutics

    Chronic Pruritus

    phase 2 small molecule completed

    1 trial

  28. VPD-737

    VYNE Therapeutics

    Epidermolysis Bullosa

    phase 2 small molecule completed

    1 trial

  29. VQW-765

    Vanda Pharmaceuticals Netherlands B.V.

    Performance Anxiety

    phase 2 small molecule completed

    1 trial

  30. VRC-HIVDNA016-00-VP

    United Therapeutics Europe Ltd

    HIV Infections

    phase 2 mab completed

    1 trial

  31. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  32. VSF-173

    Vanda Pharmaceuticals Netherlands B.V.

    Excessive Somnolence

    phase 2 small molecule completed

    1 trial

  33. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  34. VSJ-110

    Vanda Pharmaceuticals Netherlands B.V.

    Dry Eye

    phase 2 small molecule active

    2 trials

  35. VT30

    BridgeBio Oncology Therapeutics

    Venous Malformation

    phase 2 small molecule terminated

    1 trial

  36. VTX002-201

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  37. VV1

    Regeneron UK Limited

    Melanoma

    phase 2 mab active

    1 trial

  38. VX-121

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  39. VX-135

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    3 trials

  40. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Glomerulosclerosis, Focal Segmental

    phase 2 small molecule completed

    1 trial

  41. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  42. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Small Fiber Neuropathy

    phase 2 small molecule completed

    1 trial

  43. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  44. VX-152

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  45. VX-222

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    2 trials

  46. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  47. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  48. VX-371

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Ciliary Dyskinesia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.